Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 7Thoracic 4Breast 4Genitourinary 3Sarcoma 2Other solid neoplasm 2Head & Neck 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × alovudine × Other solid neoplasm × Clear all
NCT02055586 2020-09-18

FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents

Case Comprehensive Cancer Center

Completed
10 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT02146222 2019-11-18

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

University of Wisconsin, Madison

Phase 1 Completed
14 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡